Felipe Araujo Gouhie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Felipe Araujo Gouhie has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Caio Luiz Nazar Cunha
Universidade Federal de Uberlândia
2 shared publicationsLucas Figueira Vieira
Universidade Federal de Uberlândia
2 shared publications- Amanda Machado
Faculdade de Medicina Universidade Estadual Paulista, Botucatu-SP, Brazil
1 shared publication Ana Clara Nogueira Cezar
Universidade Federal de Uberlândia
1 shared publication- Ana Clara Nogueira Cezar
Universidade Federal de Uberlândia
1 shared publication Beatriz Rizzo Parreira
Universidade Federal de Uberlândia
1 shared publication
Latest Publications
- 27 October 2025
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-7
Melatonin Compared to Other Treatments for Episodic Migraine: A Systematic Review and Network Meta-Analysis
Introduction: Migraine is one of the most common neurological diseases, presenting different characteristics among patients. Therefore, there is a need to identify preventive medications that offer more efficacy and fewer adverse effects. Melatonin is a promising therapeutic alternative in this context due to its analgesic, neuromodulatory and cerebral blood flow regulatory mechanism. Objective: This study aims to evaluate the efficacy of melatonin treatment compared to placebo and other drugs in reducing migraine episodes’ frequency and secondary outcomes by analyzing randomized clinical trials. Methods: The databases Cochrane, Embase and PubMed were used to search and select relevant studies, according to their specific inclusion criteria. Afterward, the relevant data was extracted, and statistical analysis was conducted with R Studio version 4.3.1, applying appropriate models to maintain heterogeneity within them and produce a combined estimate. Results were interpreted considering potential biases and limitations to form our final statement with the Risk of Bias (RoB 2.0) tool from Cochrane. Results: A total of nine studies involving 783 patients were included in our analysis. Treatment methods were composed of seven different strategies. The network meta-analysis showed no statistically significant differences related to monthly headache frequency between melatonin and amitriptyline (SD: −1.8; 95% Crl [−5.2, 1.0]); naproxen (SD: −0.98; 95% Crl [−5.5, 3.8]); valproic acid (SD: −0.60; 95% Crl [−5., 3.6]); topiramate (SD: 0.081; 95% Crl [−5.0, 4.7]); propanolol (SD: 1.4; 95% Crl [−3.7, 6.6]) and placebo (SD: 0.49; 95% Crl [−1.6, 2.7]). Other outcomes assessed were the MIDAS score, the mean number of analgesics used and headache duration, in hours, all of which had nonsignificant differences among treatment arms. Conclusion: This systematic review and network meta-analysis found no substantial support for the efficacy of melatonin treatment in patients with episodic migraine, challenging the assumption of their correlation. Although the results showed no significant association between the disease and melatonin administration, more research is necessary to explore the influence of melatonin in migraine’s pathophysiology and further potential indirect mechanisms by which melatonin usage could benefit those who have not responded to conventional therapies.
- 27 October 2025
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- p. 1-7
Melatonin Compared to Other Treatments for Episodic Migraine: A Systematic Review and Network Meta-Analysis
Introduction: Migraine is one of the most common neurological diseases, presenting different characteristics among patients. Therefore, there is a need to identify preventive medications that offer more efficacy and fewer adverse effects. Melatonin is a promising therapeutic alternative in this context due to its analgesic, neuromodulatory and cerebral blood flow regulatory mechanism. Objective: This study aims to evaluate the efficacy of melatonin treatment compared to placebo and other drugs in reducing migraine episodes’ frequency and secondary outcomes by analyzing randomized clinical trials. Methods: The databases Cochrane, Embase and PubMed were used to search and select relevant studies, according to their specific inclusion criteria. Afterward, the relevant data was extracted, and statistical analysis was conducted with R Studio version 4.3.1, applying appropriate models to maintain heterogeneity within them and produce a combined estimate. Results were interpreted considering potential biases and limitations to form our final statement with the Risk of Bias (RoB 2.0) tool from Cochrane. Results: A total of nine studies involving 783 patients were included in our analysis. Treatment methods were composed of seven different strategies. The network meta-analysis showed no statistically significant differences related to monthly headache frequency between melatonin and amitriptyline (SD: −1.8; 95% Crl [−5.2, 1.0]); naproxen (SD: −0.98; 95% Crl [−5.5, 3.8]); valproic acid (SD: −0.60; 95% Crl [−5., 3.6]); topiramate (SD: 0.081; 95% Crl [−5.0, 4.7]); propanolol (SD: 1.4; 95% Crl [−3.7, 6.6]) and placebo (SD: 0.49; 95% Crl [−1.6, 2.7]). Other outcomes assessed were the MIDAS score, the mean number of analgesics used and headache duration, in hours, all of which had nonsignificant differences among treatment arms. Conclusion: This systematic review and network meta-analysis found no substantial support for the efficacy of melatonin treatment in patients with episodic migraine, challenging the assumption of their correlation. Although the results showed no significant association between the disease and melatonin administration, more research is necessary to explore the influence of melatonin in migraine’s pathophysiology and further potential indirect mechanisms by which melatonin usage could benefit those who have not responded to conventional therapies.
- Open Access
- 1 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (06) , 001-008
Statin versus no statin after treatment with pipeline embolization device for intracranial aneurysms: a meta-analysis
Some studies demonstrated the role of statin therapy in improving outcomes after coil embolization or surgical clipping of cerebral aneurysm. However, the benefit of statins after pipeline embolization device (PED) for intracranial aneurysms is not well established. To evaluate the effects of statins on hemorrhagic and ischemic complications as well as on complete occlusion of aneurysm in the treatment with PED. We searched the PubMed, Embase, and Cochrane Library databases for articles published from their inception to November 2024. Data were collected from observational studies comparing statin to no statin therapy following pipeline embolization. Four studies were included, comprising 2,822 patients and 3,063 aneurysms, 127 of which were ruptured and 4 of which received adjunctive coil embolization. Total hemorrhagic complication was reduced in the statin group (risk ratio [RR] = 0.50; 95%CI: 0.29–0.85; p = 0.010; I2 = 0%) but did not reveal difference in restricted propensity score-matched (PSM) analysis (RR= 0.50; 95%CI: 0.24–1.07 p = 0.073; I2 = 27%). There was no difference between the groups in complete occlusion of aneurysm rate at the last follow-up (RR = 0.94; 95%CI: 0.88–1.00; p = 0.055; I2 = 8.0%) or total ischemic complications (RR = 1.48; 95%CI: 1.06–2.07; p = 0.021; I2 = 0%). Statin use significantly reduced hemorrhagic complications after PED; however, this result should be interpreted cautiously due to study limitations. No significant differences were noted in complete occlusion rates or ischemic complications between the groups. Conceptualization: LGS; Data curation: NB, BH, AM; Formal analysis: LGS, NB, FG, LB; Validation: NB, FG; Visualization: FG, NB, BH; Writing - original draft: NB, BH, AM; Writing - review & editing: NB, LGS, JPMT, LB; Investigation: NB, FG; Project administration: LGS. The data that support the findings of the present study are available from the corresponding author, LGS, upon reasonable request. Editor-in-Chief: Ayrton Roberto Massaro 0000-0002-0487-5299. Associate Editor: Antonio Arauz Góngora 0000-0002-3340-4138. Received: 21 December 2024 Accepted: 03 March 2025 Article published online: 21 June 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil
- 1 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (06) , 001-008
Open AccessStatin versus no statin after treatment with pipeline embolization device for intracranial aneurysms: a meta-analysis
Some studies demonstrated the role of statin therapy in improving outcomes after coil embolization or surgical clipping of cerebral aneurysm. However, the benefit of statins after pipeline embolization device (PED) for intracranial aneurysms is not well established. To evaluate the effects of statins on hemorrhagic and ischemic complications as well as on complete occlusion of aneurysm in the treatment with PED. We searched the PubMed, Embase, and Cochrane Library databases for articles published from their inception to November 2024. Data were collected from observational studies comparing statin to no statin therapy following pipeline embolization. Four studies were included, comprising 2,822 patients and 3,063 aneurysms, 127 of which were ruptured and 4 of which received adjunctive coil embolization. Total hemorrhagic complication was reduced in the statin group (risk ratio [RR] = 0.50; 95%CI: 0.29–0.85; p = 0.010; I2 = 0%) but did not reveal difference in restricted propensity score-matched (PSM) analysis (RR= 0.50; 95%CI: 0.24–1.07 p = 0.073; I2 = 27%). There was no difference between the groups in complete occlusion of aneurysm rate at the last follow-up (RR = 0.94; 95%CI: 0.88–1.00; p = 0.055; I2 = 8.0%) or total ischemic complications (RR = 1.48; 95%CI: 1.06–2.07; p = 0.021; I2 = 0%). Statin use significantly reduced hemorrhagic complications after PED; however, this result should be interpreted cautiously due to study limitations. No significant differences were noted in complete occlusion rates or ischemic complications between the groups. Conceptualization: LGS; Data curation: NB, BH, AM; Formal analysis: LGS, NB, FG, LB; Validation: NB, FG; Visualization: FG, NB, BH; Writing - original draft: NB, BH, AM; Writing - review & editing: NB, LGS, JPMT, LB; Investigation: NB, FG; Project administration: LGS. The data that support the findings of the present study are available from the corresponding author, LGS, upon reasonable request. Editor-in-Chief: Ayrton Roberto Massaro 0000-0002-0487-5299. Associate Editor: Antonio Arauz Góngora 0000-0002-3340-4138. Received: 21 December 2024 Accepted: 03 March 2025 Article published online: 21 June 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil
- Open Access
- 14 May 2025
- Published by Wiley in Neuroprotection
- Vol. 3 (2) , 165-171
Vitamin E for intraventricular hemorrhage prevention in preterm neonates: A systematic review and meta‐analysis
Background: Some research suggests that vitamin E may help prevent intraventricular hemorrhage (IVH) in preterm neonates. However, consolidated evidence regarding its effects on brain vascular health in this population is lacking. This study systematically reviews primary research on this topic. This study examines the effectiveness of vitamin E supplementation in preventing IVH in preterm neonates than a placebo, thus addressing gaps in the literature.Methods: The Cochrane, Dimensions, Embase, and PubMed databases were searched for relevant studies based on specific inclusion criteria. Subsequently, the relevant data were extracted, and statistical analysis was conducted using R studio (version 4.3.1) by applying appropriate models to account for heterogeneity and generate a combined estimate. The results were interpreted considering potential biases and limitations.Results: Five studies involving 554 patients were included. Among them, 274 (49.45%) received vitamin E. The results (relative ratio 0.57; 95% confidence interval 0.35–0.92; p = 0.02; I2 = 56%) demonstrated a reduction in the incidence of IVH in patients who received administration of vitamin E (n = 274) compared with those who received a placebo (n = 280).Conclusion: These findings highlight the potential therapeutic benefits of vitamin E supplementation in preterm neonates, which show a significant reduction in IVH incidence than placebo. Further research and clinical trials are required to fully explore its protective effects in this population.
- 14 May 2025
- Published by Wiley in Neuroprotection
- Vol. 3 (2) , 165-171
Open AccessVitamin E for intraventricular hemorrhage prevention in preterm neonates: A systematic review and meta‐analysis
Background: Some research suggests that vitamin E may help prevent intraventricular hemorrhage (IVH) in preterm neonates. However, consolidated evidence regarding its effects on brain vascular health in this population is lacking. This study systematically reviews primary research on this topic. This study examines the effectiveness of vitamin E supplementation in preventing IVH in preterm neonates than a placebo, thus addressing gaps in the literature.Methods: The Cochrane, Dimensions, Embase, and PubMed databases were searched for relevant studies based on specific inclusion criteria. Subsequently, the relevant data were extracted, and statistical analysis was conducted using R studio (version 4.3.1) by applying appropriate models to account for heterogeneity and generate a combined estimate. The results were interpreted considering potential biases and limitations.Results: Five studies involving 554 patients were included. Among them, 274 (49.45%) received vitamin E. The results (relative ratio 0.57; 95% confidence interval 0.35–0.92; p = 0.02; I2 = 56%) demonstrated a reduction in the incidence of IVH in patients who received administration of vitamin E (n = 274) compared with those who received a placebo (n = 280).Conclusion: These findings highlight the potential therapeutic benefits of vitamin E supplementation in preterm neonates, which show a significant reduction in IVH incidence than placebo. Further research and clinical trials are required to fully explore its protective effects in this population.
- Open Access
- 25 August 2023
- Published by Elsevier in Brain Disorders
- Vol. 11
Sceletium tortuosum effects on anxiety: A systematic review and meta-analysis
- 25 August 2023
- Published by Elsevier in Brain Disorders
- Vol. 11
Open AccessSceletium tortuosum effects on anxiety: A systematic review and meta-analysis